Prophylactic platelet transfusions in patients with blood malignancies: Cost analysis of a randomized trial

Transfusion

Volumn 54, Issue 10, 2014, Pages 2394-2403

  Campbell, Helen E ^a   Estcourt, Lise J ^a,b,c   Stokes, Elizabeth A ^a   Llewelyn, Charlotte A ^a,b,c   Murphy, Michael F ^a,b,c   Wood, Erica M ^d   Stanworth, Simon J ^a,b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; COST BENEFIT ANALYSIS; ERYTHROCYTE; FEMALE; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; THROMBOCYTE TRANSFUSION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED STUDY; ECONOMICS; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; MIDDLE AGED; MULTICENTER STUDY; PRIMARY PREVENTION; PROCEDURES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; COST-BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COSTS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; PRIMARY PREVENTION; QUALITY OF LIFE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84908105937     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12697     Document Type: Article

References (17)

1. Riley W, Smalley B, Pulkrabek S, et al. Using lean techniques to define the platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion strategies. Transfusion 2012; 52: 1957-1967.
2. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-613.
3. Kacker S, Frick KD, Tobian AA,. The costs of transfusion: economic evaluations in transfusion medicine, Part 1. Transfusion 2013; 53: 1383-1385.
4. Kacker S, Frick KD, Tobian AA,. Establishing a framework: economic evaluations in transfusion medicine, Part 2. Transfusion 2013; 53: 1634-1636.
5. Kacker S, Frick KD, Tobian AA,. Constructing a model: economic evaluations in transfusion medicine, Part 3. Transfusion 2013; 53: 1885-1887.
6. Kacker S, Frick KD, Tobian AA,. Data and interpretation: economic evaluations in transfusion medicine, Part 4. Transfusion 2013; 53: 2130-2133.
7. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers. N Engl J Med 2013; 368: 1771-1780.
8. Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010; 24: 163-171.
9. Organisation for Economic Co-operation and Development (OECD). PPP Benchmark Results 2008. [cited 2013 May 9]. Available from: http://stats.oecd.org/
10. Efron B, Tibshirani R,. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986; 1: 54-77.
11. Stanworth SJ, Estcourt LJ, Llewelyn CA, Murphy MF, Wood EM,; TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion 2014. doi: 10.1111/trf.12646/pdf.
12. Cella DF,. Quality of life: concepts and definition. J Pain Symptom Manage 1994; 9: 186-192.
13. Estcourt LJ, Pinchon D, Symington E, et al. Does bleeding affect patient reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review. Transfusion 2014; 54: 1166-1179.
14. Fogarty PF, Tarantino MD, Brainsky A, et al. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin 2012; 28: 79-87.
15. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380: 1309-1316.
16. Glick H, Doshi J, Sonnard S, et al. Economic evaluation in clinical trials. Oxford, UK: Oxford University Press; 2007.
17. Estcourt LJ, Stanworth SJ, Murphy MF,. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol 2011; 154: 425-440.